

Peter Du

Ph.D. Student in Cancer Biology, admitted Summer 2020

Publications

PUBLICATIONS

- **GLIOMA SYNAPSES RECRUIT MECHANISMS OF ADAPTIVE PLASTICITY**

Taylor, K., Barron, T., Zhang, H., Hui, A., Hartmann, G., Ni, L., Venkatesh, H., Du, P., Mancusi, R., Yalcin, B., Chau, I., Ponnuswami, A., Aziz-Bose, et al
OXFORD UNIV PRESS INC.2022: 25

- **Systematic discovery of recombinases for efficient integration of large DNA sequences into the human genome.** *Nature biotechnology*

Durrant, M. G., Fanton, A., Tycko, J., Hinks, M., Chandrasekaran, S. S., Perry, N. T., Schaepe, J., Du, P. P., Lotfy, P., Bassik, M. C., Bintu, L., Bhatt, A. S., Hsu, et al
2022

- **In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer.** *Nature immunology*

Dubrot, J., Du, P. P., Lane-Reticker, S. K., Kessler, E. A., Muscato, A. J., Mehta, A., Freeman, S. S., Allen, P. M., Olander, K. E., Ockerman, K. M., Wolfe, C. H., Wiesmann, F., Knudsen, et al
2022

- **Pathogenic or benign?** *Nature biotechnology*

Du, P. P., Liu, K., Bassik, M. C., Hess, G. T.
2022

- **Checkpoint blockade-induced CD8+T cell differentiation in head and neck cancer responders** *JOURNAL FOR IMMUNOTHERAPY OF CANCER*

Zhou, L., Zeng, Z., Egloff, A., Zhang, F., Guo, F., Campbell, K. M., Du, P., Fu, J., Zolkind, P., Ma, X., Zhang, Z., Zhang, Y., Wang, et al
2022; 10 (1)

- **Epigenetic silencing by SETDB1 suppresses tumour intrinsic immunogenicity** *NATURE*

Griffin, G. K., Wu, J., Iracheta-Vellve, A., Patti, J. C., Hsu, J., Davis, T., Dele-Oni, D., Du, P. P., Halawi, A. G., Ishizuka, J. J., Kim, S. Y., Klaeger, S., Knudsen, et al
2021; 595 (7866): 309+

- **In vivo screens using a selective CRISPR antigen removal lentiviral vector system reveal immune dependencies in renal cell carcinoma** *IMMUNITY*

Dubrot, J., Lane-Reticker, S., Kessler, E. A., Ayer, A., Mishra, G., Wolfe, C. H., Zimmer, M. D., Du, P. P., Mahapatra, A., Ockerman, K. M., Davis, T. R., Kohnle, I. C., Pope, et al
2021; 54 (3): 571+

- **Loss of ADARI in tumours overcomes resistance to immune checkpoint blockade.** *Nature*

Ishizuka, J. J., Manguso, R. T., Cheruiyot, C. K., Bi, K. n., Panda, A. n., Iracheta-Vellve, A. n., Miller, B. C., Du, P. P., Yates, K. B., Dubrot, J. n., Buchumenski, I. n., Comstock, D. E., Brown, et al
2019; 565 (7737): 43–48